Singapore, Aug. 18 -- US-based startup Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, has announced a strategic research collaboration with Merck KGaA, Darmstadt,Germany, a leading science and technology company.

The collaboration will focus on the discovery of novel RNA-targeting small molecules in select neurological indications with high unmet medical need.

Under the terms of the agreement, Skyhawk will use its proprietary SkySTAR(R)(Skyhawk Smallmolecule Therapeutics for Alternative splicing of RNA) platform to identify small molecule candidates directed at specific RNA targets designated by Merck KGaA, Darmstadt,Germany.

The collaboration aims to expand the po...